Behaviorally active oxytocin fragments simultaneously attenuate heroin self-administration and tolerance in rats

G. Kovács, Jan M. Van Ree

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Maintenance of intravenous heroin self-administration and the degree of tolerance to the analgesic effect of self-injected heroin were simultaneously measured in heroin-tolerant rats. Subcutaneous injection of oxytocin (OXT-(1-9)) and of its behaviorally active fragments desglycinamide9 -oxytocin (OXT-(1-8)) and [pGlu4, Cyt6]-oxytocin-(4-8) (OXT-(4-8)) decreased the amount of heroin self-injected. The C-terminal tripeptide of oxytocin (prolyl-leucyl-glycinamide, PLG, OXT-(7-9)) and desglycinamide9-[Arg]8-vasopressin (AVP-(1-8)) were ineffective in this respect. In spite of the lower amount of self-injected heroin after pretreatment with oxytocin fragments, no differences in the antinociceptive effect of self-injected heroin, as assessed by the lick response using a hot plate device, were observed after pretreatment with placebo and oxytocin fragments. These findings suggest that oxytocin and some of its behaviorally active fragments attenuate heroin tolerance and that this effect may result in a diminished heroin intake in tolerant animals self-injecting heroin.

Original languageEnglish
Pages (from-to)1895-1900
Number of pages6
JournalLife Sciences
Volume37
Issue number20
DOIs
Publication statusPublished - Nov 18 1985

Fingerprint

Self Tolerance
Self Administration
Heroin
Oxytocin
Rats
MSH Release-Inhibiting Hormone
Arginine Vasopressin
Subcutaneous Injections
Vasopressins
Analgesics
Animals
Placebos
Maintenance
Equipment and Supplies

ASJC Scopus subject areas

  • Pharmacology

Cite this

Behaviorally active oxytocin fragments simultaneously attenuate heroin self-administration and tolerance in rats. / Kovács, G.; Van Ree, Jan M.

In: Life Sciences, Vol. 37, No. 20, 18.11.1985, p. 1895-1900.

Research output: Contribution to journalArticle

@article{fa8af90c5dc8462b8be83673b2821799,
title = "Behaviorally active oxytocin fragments simultaneously attenuate heroin self-administration and tolerance in rats",
abstract = "Maintenance of intravenous heroin self-administration and the degree of tolerance to the analgesic effect of self-injected heroin were simultaneously measured in heroin-tolerant rats. Subcutaneous injection of oxytocin (OXT-(1-9)) and of its behaviorally active fragments desglycinamide9 -oxytocin (OXT-(1-8)) and [pGlu4, Cyt6]-oxytocin-(4-8) (OXT-(4-8)) decreased the amount of heroin self-injected. The C-terminal tripeptide of oxytocin (prolyl-leucyl-glycinamide, PLG, OXT-(7-9)) and desglycinamide9-[Arg]8-vasopressin (AVP-(1-8)) were ineffective in this respect. In spite of the lower amount of self-injected heroin after pretreatment with oxytocin fragments, no differences in the antinociceptive effect of self-injected heroin, as assessed by the lick response using a hot plate device, were observed after pretreatment with placebo and oxytocin fragments. These findings suggest that oxytocin and some of its behaviorally active fragments attenuate heroin tolerance and that this effect may result in a diminished heroin intake in tolerant animals self-injecting heroin.",
author = "G. Kov{\'a}cs and {Van Ree}, {Jan M.}",
year = "1985",
month = "11",
day = "18",
doi = "10.1016/0024-3205(85)90007-4",
language = "English",
volume = "37",
pages = "1895--1900",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "20",

}

TY - JOUR

T1 - Behaviorally active oxytocin fragments simultaneously attenuate heroin self-administration and tolerance in rats

AU - Kovács, G.

AU - Van Ree, Jan M.

PY - 1985/11/18

Y1 - 1985/11/18

N2 - Maintenance of intravenous heroin self-administration and the degree of tolerance to the analgesic effect of self-injected heroin were simultaneously measured in heroin-tolerant rats. Subcutaneous injection of oxytocin (OXT-(1-9)) and of its behaviorally active fragments desglycinamide9 -oxytocin (OXT-(1-8)) and [pGlu4, Cyt6]-oxytocin-(4-8) (OXT-(4-8)) decreased the amount of heroin self-injected. The C-terminal tripeptide of oxytocin (prolyl-leucyl-glycinamide, PLG, OXT-(7-9)) and desglycinamide9-[Arg]8-vasopressin (AVP-(1-8)) were ineffective in this respect. In spite of the lower amount of self-injected heroin after pretreatment with oxytocin fragments, no differences in the antinociceptive effect of self-injected heroin, as assessed by the lick response using a hot plate device, were observed after pretreatment with placebo and oxytocin fragments. These findings suggest that oxytocin and some of its behaviorally active fragments attenuate heroin tolerance and that this effect may result in a diminished heroin intake in tolerant animals self-injecting heroin.

AB - Maintenance of intravenous heroin self-administration and the degree of tolerance to the analgesic effect of self-injected heroin were simultaneously measured in heroin-tolerant rats. Subcutaneous injection of oxytocin (OXT-(1-9)) and of its behaviorally active fragments desglycinamide9 -oxytocin (OXT-(1-8)) and [pGlu4, Cyt6]-oxytocin-(4-8) (OXT-(4-8)) decreased the amount of heroin self-injected. The C-terminal tripeptide of oxytocin (prolyl-leucyl-glycinamide, PLG, OXT-(7-9)) and desglycinamide9-[Arg]8-vasopressin (AVP-(1-8)) were ineffective in this respect. In spite of the lower amount of self-injected heroin after pretreatment with oxytocin fragments, no differences in the antinociceptive effect of self-injected heroin, as assessed by the lick response using a hot plate device, were observed after pretreatment with placebo and oxytocin fragments. These findings suggest that oxytocin and some of its behaviorally active fragments attenuate heroin tolerance and that this effect may result in a diminished heroin intake in tolerant animals self-injecting heroin.

UR - http://www.scopus.com/inward/record.url?scp=0022383564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022383564&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(85)90007-4

DO - 10.1016/0024-3205(85)90007-4

M3 - Article

VL - 37

SP - 1895

EP - 1900

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 20

ER -